

Overcoming the challenges within the **bioanalytical matrices supply chain**

An increase in demand for matrix supplies – caused by COVID-19 vaccine and therapeutic development to tackle the pandemic, as well as logistical challenges with sourcing and transporting matrices – has led to an increase in lead times for multiple matrices and reduction in supply.

This infographic will explore the challenges faced within the bioanalytical matrix supply chain and how Labcorp’s mitigation strategies can be implemented to alleviate the strain on supply.

What factors are causing supply chain strain?

Due to the recent pandemic, many factors have contributed to the strain on the biological matrix supply chain. These include:

2,500+
 COVID-19 clinical trials alone

400%-600%
 increase in lead times for NHP matrices due to export restrictions, permit delays and trade relations

10x cost increase
 for some NHP matrices VS. pre-pandemic norms

Reduced supply
 of human matrices due to increased demand, decreased donors and blood collection device issues

What needs to be done to solve these supply chain issues?

Biological matrix shortages can cause delays—potentially significant—in drug development programs across the pharmaceutical and biotechnology industries. To overcome this, effective industry strategies are needed to help maintain clinical trial progression.

What mitigation strategies can be utilized?

Labcorp Bioanalytical Services are implementing several mitigation strategies in order to resolve the matrix supply strain, which include:

- Projecting matrix needs far in advance
- Additional matrix draws and/or repurposing of matrices
- Options to use surrogate matrices presented to clients
- iChem automation development

This infographic has been created as part of a Bioanalysis Zone feature in association with Labcorp.